*Bipolar Disorder Cystectomy Humans *Urinary Bladder Neoplasms/surgery Urologic Surgical Procedures

bladder cancer checkpoint inhibitors chemotherapy immunotherapy radical cystectomy design of the study in the collection analyses or interpretation of data in the writing of the manuscript or in the decision to publish the results.

Cohort Studies Humans *Hypertension *Metabolic Syndrome/epidemiology Obesity Risk Factors *Urinary Bladder Neoplasms/epidemiology Meta analysis Metabolic syndrome Metabolic syndrome components Urinary bladder neoplasm this study.

Biomarkers Tumor *Carcinoma Transitional Cell/diagnosis Female Humans Male Nuclear Proteins Sensitivity and Specificity *Urinary Bladder Neoplasms/diagnosis/pathology bladder tumor diagnosis meta analysis nuclear matrix protein urine cytology

Cisplatin/adverse effects Humans *Immunotherapy/adverse effects/methods *Muscles/pathology *Neoadjuvant Therapy/adverse effects Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/pathology/therapy chemoimmunotherapy immunotherapy meta-analysis muscle-invasive bladder cancer (MIBC) neoadjuvant commercial or financial relationships that could be construed as a potential conflict of interest.

Humans *Urinary Bladder Neoplasms/surgery/pathology Neoplasm Recurrence Local/pathology Cystectomy/methods Cystoscopy/methods Light #BladderCancer #blcsm #uroonc blue light non-muscle-invasive bladder cancer photodynamic diagnosis transurethral resection of the bladder white light

Bayes Theorem Cystectomy Humans *Laparoscopy Postoperative Complications/surgery *Robotic Surgical Procedures *Robotics Treatment Outcome *Urinary Bladder Neoplasms/surgery

Humans *Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/pathology Infusions Intra-Arterial Chemotherapy Adjuvant Adverse Reactions bladder cancer intra-arterial chemotherapy meta-analysis prognosis

Humans Magnetic Resonance Imaging *Multiparametric Magnetic Resonance Imaging Muscles Prospective Studies Urinary Bladder *Urinary Bladder Neoplasms/diagnostic imaging Bladder cancer Meta-analysis Muscle invasion Vesical imaging-reporting and data system

Humans Immunotherapy Inflammation Prognosis Progression-Free Survival *Urinary Bladder Neoplasms

Bcg Bacillus Calmette–Guérin Nmibc bladder cancer checkpoint inhibition therapy nadofaragene firadenovec non muscle invasive oncolytic viruses

Cystectomy/methods Humans Quality of Life *Urinary Bladder Neoplasms/surgery *Urinary Diversion/methods *Urinary Reservoirs Continent nursing systematic review urinary diversion

Female Gene Expression Profiling Gene Regulatory Networks Humans Male Muscles Neoplasm Invasiveness Prognosis *Urinary Bladder Neoplasms/genetics/metabolism rab GTP-Binding Proteins/genetics/metabolism Bladder cancer Gene expression Muscle-invasive bladder cancer Urothelial cancer

Area Under Curve *Carcinoma Transitional Cell Humans In Situ Hybridization Fluorescence ROC Curve Sensitivity and Specificity *Urinary Bladder Neoplasms/pathology Biomarker Cytology Diagnostic Fluorescent in situ hybridization (FISH) Meta-analysis Upper urinary tract urothelial carcinoma (UTUC)

Antibodies Monoclonal Humanized/*therapeutic use *Carcinoma Transitional Cell/drug therapy Humans Prognosis Retrospective Studies *Urinary Bladder Neoplasms/drug therapy Metastatic urothelial carcinoma Pembrolizumab Prognostic factor Janssen and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas Bayer Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Consulting or Advisory Role: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Speakers Bureau: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen Movember Foundation. The other authors declare no conflicts of interest associated with this manuscript.

Humans Female Male Infant *Urinary Bladder Neoplasms/diagnosis/therapy/pathology *Carcinoma Transitional Cell/pathology Urinary Bladder/pathology Neoplasm Staging Cystoscopy Cystectomy/methods

Bladder cancer neoadjuvant chemotherapy radical cystectomy systematic review variant histology urothelial cancer

Adjuvants Immunologic Administration Intravesical BCG Vaccine/therapeutic use Bayes Theorem *Covid-19 Duration of Therapy Humans *Mycobacterium bovis Neoplasm Invasiveness Neoplasm Recurrence Local/drug therapy Network Meta-Analysis Pandemics *Urinary Bladder Neoplasms/drug therapy *Urology

*Carcinoma Renal Cell/complications/epidemiology *Carcinoma Transitional Cell/complications/epidemiology Cross-Sectional Studies Hematuria/epidemiology/etiology Humans Incidence *Kidney Neoplasms/complications/epidemiology Male Prospective Studies Retrospective Studies Risk Factors *Urinary Bladder Neoplasms/complications/epidemiology Age distribution Cystoscopy Haematuria Kidney neoplasms Radiotherapy Sex Smoking Transitional cell carcinoma Urinary bladder neoplasms Urological neoplasms

Humans Female Male *Urinary Bladder Neoplasms/etiology/microbiology RNA Ribosomal 16S/genetics Urinary Bladder/microbiology *Microbiota/genetics Bacteria/genetics Bladder cancer Gender Urinary microbiota Uropathogens of interest.